ATOMO DIAGNOSTICS LIMITED - Announcements

Market Cap $14.70M Add to my watchlist

Healthcare Medical Devices

Atomo Diagnostics Limited is an Australia-based medical device company. The Company... Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

AT1	2024 Appendix 4E and Annual Report	PRICE SENSITIVE	29/08/24	1.1MB	Share
AT1	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	25/07/24	1.03MB	Share
AT1	Government funded procurement of Atomo HIV tests commencing	PRICE SENSITIVE	12/06/24	300.51KB	Share
AT1	Significant funding to HIV Self-Testing in Federal Budget	PRICE SENSITIVE	16/05/24	250.84KB	Share
AT1	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/04/24	958.52KB	Share
AT1	AT1 secures significant order for HIV self-tests	PRICE SENSITIVE	15/04/24	135.35KB	Share
AT1	AT1 secures significant order for HIV self tests for LMIC	PRICE SENSITIVE	06/03/24	89.48KB	Share
AT1	Appendix 4D and Half Year Report ended 31 Dec 2023	PRICE SENSITIVE	26/02/24	367.79KB	Share
AT1	Quarterly Activity Report - 31 December 2023	PRICE SENSITIVE	29/01/24	630.28KB	Share
AT1	Appendix 4C - 31 December 2023	PRICE SENSITIVE	29/01/24	810.62KB	Share
AT1	Quarterly Activity Report - 30 September 2023	PRICE SENSITIVE	26/10/23	162.18KB	Share
AT1	Appendix 4C - 30 September 2023	PRICE SENSITIVE	26/10/23	834.17KB	Share
AT1	HIV Self-Test - Market Update	PRICE SENSITIVE	20/10/23	171.8KB	Share
AT1	2023 Appendix 4E and Annual Report	PRICE SENSITIVE	24/08/23	950.22KB	Share
AT1	Quarterly Activity Report - 30 June 2023	PRICE SENSITIVE	27/07/23	167.68KB	Share
AT1	Appendix 4C - 30 June 2023	PRICE SENSITIVE	27/07/23	809.78KB	Share
AT1	Investor Presentation - Placement and SPP	PRICE SENSITIVE	13/07/23	4.54MB	Share
AT1	Atomo Completes Placement and Launches SPP	PRICE SENSITIVE	13/07/23	203.66KB	Share
AT1	Trading Halt	PRICE SENSITIVE	11/07/23	273.59KB	Share
AT1	Price Movement Clarification	PRICE SENSITIVE	04/07/23	135.31KB	Share
AT1	Exclusive Agreement for HIV Testing Signed with Newfoundland	PRICE SENSITIVE	14/06/23	172.81KB	Share
AT1	Quarterly Activity Report - 31 March 2023	PRICE SENSITIVE	27/04/23	162.09KB	Share
AT1	Appendix 4C - 31 March 2023	PRICE SENSITIVE	27/04/23	805.69KB	Share
AT1	A$1.9m contract - South Africa HIV Self-Test private market	PRICE SENSITIVE	05/04/23	146.89KB	Share
AT1	Significant Purchase Order for HIV Self-Tests for Europe	PRICE SENSITIVE	28/02/23	138.77KB	Share
AT1	Investor Presentation	PRICE SENSITIVE	23/02/23	1.18MB	Share
AT1	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/23	469.08KB	Share
AT1	Quarterly Activity Report - 31 December 2022	PRICE SENSITIVE	27/01/23	194.58KB	Share
AT1	Appendix 4C - 31 December 2022	PRICE SENSITIVE	27/01/23	831.22KB	Share
AT1	Agreement for Rapid Pregnancy Tests Signed with NG Biotech	PRICE SENSITIVE	18/01/23	192.04KB	Share
AT1	Quarterly Activity Report - 30 September 2022	PRICE SENSITIVE	25/10/22	167.27KB	Share
AT1	Appendix 4C - 30 September 2022	PRICE SENSITIVE	25/10/22	809.69KB	Share
AT1	2022 Appendix 4E and Annual Report	PRICE SENSITIVE	25/08/22	1.25MB	Share
AT1	Quarterly Activity Report - 30 June 2022	PRICE SENSITIVE	29/07/22	233.27KB	Share
AT1	Appendix 4C - 30 June 2022	PRICE SENSITIVE	29/07/22	830.13KB	Share
AT1	Quarterly Activity Report - 31 March 2022	PRICE SENSITIVE	27/04/22	198.58KB	Share
AT1	Appendix 4C - 31 March 2022	PRICE SENSITIVE	27/04/22	874.38KB	Share
AT1	Investor Presentation	PRICE SENSITIVE	21/02/22	1.33MB	Share
AT1	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	21/02/22	784.26KB	Share
AT1	Atomo receives approval for its COVID-19 antigen test in NZ	PRICE SENSITIVE	27/01/22	145.2KB	Share
AT1	Quarterly Activity Report - 31 December 2021	PRICE SENSITIVE	25/01/22	266.99KB	Share
AT1	Appendix 4C - 31 December 2021	PRICE SENSITIVE	25/01/22	808.99KB	Share
AT1	Response to ASX Price Query	PRICE SENSITIVE	30/12/21	242.7KB	Share
AT1	HIV Self-Test - improved supply & advertising conditions	PRICE SENSITIVE	26/10/21	124.29KB	Share
AT1	Quarterly Activity Report - 30 September 2021	PRICE SENSITIVE	25/10/21	277.65KB	Share
AT1	Appendix 4C - 30 September 2021	PRICE SENSITIVE	25/10/21	776.92KB	Share
AT1	Atomo and Access Bio renegotiate supply agreements	PRICE SENSITIVE	05/10/21	103.23KB	Share
AT1	Trading Halt	PRICE SENSITIVE	04/10/21	193.15KB	Share
AT1	Pause in Trading	PRICE SENSITIVE	04/10/21	117.13KB	Share
AT1	FY21 Results Presentation	PRICE SENSITIVE	27/08/21	1.94MB	Share
AT1	Appendix 4E & Annual Financial Report	PRICE SENSITIVE	27/08/21	365.91KB	Share
AT1	Quarterly Activity Report - 30 June 2021	PRICE SENSITIVE	29/07/21	316.1KB	Share
AT1	Appendix 4C - 30 June 2021	PRICE SENSITIVE	29/07/21	874.74KB	Share
AT1	Access Bio receives FDA clearance for COVID-19 antibody test	PRICE SENSITIVE	28/06/21	229.77KB	Share
AT1	Update to Atomo's US market strategy	PRICE SENSITIVE	30/04/21	154.1KB	Share
AT1	Quarterly Activity Report & Appendix 4C - 31 March 2021	PRICE SENSITIVE	30/04/21	642.38KB	Share
AT1	Viatris & Atomo to Support Unitaid HIV Self-Test Expansion	PRICE SENSITIVE	29/04/21	219.48KB	Share
AT1	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
AT1	Investor Presentation	PRICE SENSITIVE	23/02/21	2.81MB	Share
AT1	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/21	675.53KB	Share
AT1	Quarterly Activity Report & Appendix 4C - 31 December 2020	PRICE SENSITIVE	27/01/21	697.41KB	Share
AT1	Atomo provides update on its HIV Rapid Test business	PRICE SENSITIVE	07/12/20	369.13KB	Share
AT1	Atomo receives TGA approval for AtomoRapid HIV (1&2) test	PRICE SENSITIVE	10/11/20	355.89KB	Share
AT1	Managing Director's AGM Presentation	PRICE SENSITIVE	04/11/20	1.6MB	Share
AT1	Quarterly Activity Report & Appendix 4C - 30 September 2020	PRICE SENSITIVE	29/10/20	768.95KB	Share
AT1	Atomo receives TGA approval for COVID19 antigen test	PRICE SENSITIVE	27/10/20	527.41KB	Share
AT1	Trading Halt	PRICE SENSITIVE	27/10/20	308.14KB	Share
AT1	Atomo & Access Bio sign deal for rapid antigen test	PRICE SENSITIVE	29/09/20	516.59KB	Share
AT1	Pause in Trading	PRICE SENSITIVE	29/09/20	116.08KB	Share
AT1	DIVOC Labs to sell Atomo's COVID-19 test in India	PRICE SENSITIVE	23/09/20	331.29KB	Share
AT1	Pause in Trading	PRICE SENSITIVE	23/09/20	116.17KB	Share
AT1	FY20 Results Presentation	PRICE SENSITIVE	31/08/20	2.2MB	Share
AT1	Appendix 4E & Annual Financial Report	PRICE SENSITIVE	31/08/20	4.8MB	Share
AT1	Atomo receives TGA approval for COVID19 antibody test	PRICE SENSITIVE	10/08/20	236.93KB	Share
AT1	Pause in Trading	PRICE SENSITIVE	10/08/20	115.95KB	Share
AT1	Atomo & Access Bio enter North American COVID-19 partnership	PRICE SENSITIVE	28/07/20	416.4KB	Share
AT1	Quarterly Activity Report & Appendix 4C - 30 June 2020	PRICE SENSITIVE	22/07/20	505.42KB	Share
AT1	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
AT1	Atomo and NG Biotech expand COVID-19 partnership	PRICE SENSITIVE	04/06/20	382.44KB	Share
AT1	Pause in Trading	PRICE SENSITIVE	04/06/20	115.52KB	Share
AT1	Atomo receives additional order for COVID19 test devices	PRICE SENSITIVE	07/05/20	304.18KB	Share
AT1	Pause in Trading	PRICE SENSITIVE	07/05/20	115.75KB	Share

AT1 2024 Appendix 4E and Annual Report
29/08/24	PRICE SENSITIVE	1.1MB	Share
AT1 Quarterly Activities Report and Appendix 4C
25/07/24	PRICE SENSITIVE	1.03MB	Share
AT1 Government funded procurement of Atomo HIV tests commencing
12/06/24	PRICE SENSITIVE	300.51KB	Share
AT1 Significant funding to HIV Self-Testing in Federal Budget
16/05/24	PRICE SENSITIVE	250.84KB	Share
AT1 Quarterly Activities Report and Appendix 4C
29/04/24	PRICE SENSITIVE	958.52KB	Share
AT1 AT1 secures significant order for HIV self-tests
15/04/24	PRICE SENSITIVE	135.35KB	Share
AT1 AT1 secures significant order for HIV self tests for LMIC
06/03/24	PRICE SENSITIVE	89.48KB	Share
AT1 Appendix 4D and Half Year Report ended 31 Dec 2023
26/02/24	PRICE SENSITIVE	367.79KB	Share
AT1 Quarterly Activity Report - 31 December 2023
29/01/24	PRICE SENSITIVE	630.28KB	Share
AT1 Appendix 4C - 31 December 2023
29/01/24	PRICE SENSITIVE	810.62KB	Share
AT1 Quarterly Activity Report - 30 September 2023
26/10/23	PRICE SENSITIVE	162.18KB	Share
AT1 Appendix 4C - 30 September 2023
26/10/23	PRICE SENSITIVE	834.17KB	Share
AT1 HIV Self-Test - Market Update
20/10/23	PRICE SENSITIVE	171.8KB	Share
AT1 2023 Appendix 4E and Annual Report
24/08/23	PRICE SENSITIVE	950.22KB	Share
AT1 Quarterly Activity Report - 30 June 2023
27/07/23	PRICE SENSITIVE	167.68KB	Share
AT1 Appendix 4C - 30 June 2023
27/07/23	PRICE SENSITIVE	809.78KB	Share
AT1 Investor Presentation - Placement and SPP
13/07/23	PRICE SENSITIVE	4.54MB	Share
AT1 Atomo Completes Placement and Launches SPP
13/07/23	PRICE SENSITIVE	203.66KB	Share
AT1 Trading Halt
11/07/23	PRICE SENSITIVE	273.59KB	Share
AT1 Price Movement Clarification
04/07/23	PRICE SENSITIVE	135.31KB	Share
AT1 Exclusive Agreement for HIV Testing Signed with Newfoundland
14/06/23	PRICE SENSITIVE	172.81KB	Share
AT1 Quarterly Activity Report - 31 March 2023
27/04/23	PRICE SENSITIVE	162.09KB	Share
AT1 Appendix 4C - 31 March 2023
27/04/23	PRICE SENSITIVE	805.69KB	Share
AT1 A$1.9m contract - South Africa HIV Self-Test private market
05/04/23	PRICE SENSITIVE	146.89KB	Share
AT1 Significant Purchase Order for HIV Self-Tests for Europe
28/02/23	PRICE SENSITIVE	138.77KB	Share
AT1 Investor Presentation
23/02/23	PRICE SENSITIVE	1.18MB	Share
AT1 Appendix 4D and Half Year Financial Report
23/02/23	PRICE SENSITIVE	469.08KB	Share
AT1 Quarterly Activity Report - 31 December 2022
27/01/23	PRICE SENSITIVE	194.58KB	Share
AT1 Appendix 4C - 31 December 2022
27/01/23	PRICE SENSITIVE	831.22KB	Share
AT1 Agreement for Rapid Pregnancy Tests Signed with NG Biotech
18/01/23	PRICE SENSITIVE	192.04KB	Share
AT1 Quarterly Activity Report - 30 September 2022
25/10/22	PRICE SENSITIVE	167.27KB	Share
AT1 Appendix 4C - 30 September 2022
25/10/22	PRICE SENSITIVE	809.69KB	Share
AT1 2022 Appendix 4E and Annual Report
25/08/22	PRICE SENSITIVE	1.25MB	Share
AT1 Quarterly Activity Report - 30 June 2022
29/07/22	PRICE SENSITIVE	233.27KB	Share
AT1 Appendix 4C - 30 June 2022
29/07/22	PRICE SENSITIVE	830.13KB	Share
AT1 Quarterly Activity Report - 31 March 2022
27/04/22	PRICE SENSITIVE	198.58KB	Share
AT1 Appendix 4C - 31 March 2022
27/04/22	PRICE SENSITIVE	874.38KB	Share
AT1 Investor Presentation
21/02/22	PRICE SENSITIVE	1.33MB	Share
AT1 Appendix 4D and Half Year Financial Report
21/02/22	PRICE SENSITIVE	784.26KB	Share
AT1 Atomo receives approval for its COVID-19 antigen test in NZ
27/01/22	PRICE SENSITIVE	145.2KB	Share
AT1 Quarterly Activity Report - 31 December 2021
25/01/22	PRICE SENSITIVE	266.99KB	Share
AT1 Appendix 4C - 31 December 2021
25/01/22	PRICE SENSITIVE	808.99KB	Share
AT1 Response to ASX Price Query
30/12/21	PRICE SENSITIVE	242.7KB	Share
AT1 HIV Self-Test - improved supply & advertising conditions
26/10/21	PRICE SENSITIVE	124.29KB	Share
AT1 Quarterly Activity Report - 30 September 2021
25/10/21	PRICE SENSITIVE	277.65KB	Share
AT1 Appendix 4C - 30 September 2021
25/10/21	PRICE SENSITIVE	776.92KB	Share
AT1 Atomo and Access Bio renegotiate supply agreements
05/10/21	PRICE SENSITIVE	103.23KB	Share
AT1 Trading Halt
04/10/21	PRICE SENSITIVE	193.15KB	Share
AT1 Pause in Trading
04/10/21	PRICE SENSITIVE	117.13KB	Share
AT1 FY21 Results Presentation
27/08/21	PRICE SENSITIVE	1.94MB	Share
AT1 Appendix 4E & Annual Financial Report
27/08/21	PRICE SENSITIVE	365.91KB	Share
AT1 Quarterly Activity Report - 30 June 2021
29/07/21	PRICE SENSITIVE	316.1KB	Share
AT1 Appendix 4C - 30 June 2021
29/07/21	PRICE SENSITIVE	874.74KB	Share
AT1 Access Bio receives FDA clearance for COVID-19 antibody test
28/06/21	PRICE SENSITIVE	229.77KB	Share
AT1 Update to Atomo's US market strategy
30/04/21	PRICE SENSITIVE	154.1KB	Share
AT1 Quarterly Activity Report & Appendix 4C - 31 March 2021
30/04/21	PRICE SENSITIVE	642.38KB	Share
AT1 Viatris & Atomo to Support Unitaid HIV Self-Test Expansion
29/04/21	PRICE SENSITIVE	219.48KB	Share
AT1 S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
AT1 Investor Presentation
23/02/21	PRICE SENSITIVE	2.81MB	Share
AT1 Appendix 4D and Half Year Financial Report
23/02/21	PRICE SENSITIVE	675.53KB	Share
AT1 Quarterly Activity Report & Appendix 4C - 31 December 2020
27/01/21	PRICE SENSITIVE	697.41KB	Share
AT1 Atomo provides update on its HIV Rapid Test business
07/12/20	PRICE SENSITIVE	369.13KB	Share
AT1 Atomo receives TGA approval for AtomoRapid HIV (1&2) test
10/11/20	PRICE SENSITIVE	355.89KB	Share
AT1 Managing Director's AGM Presentation
04/11/20	PRICE SENSITIVE	1.6MB	Share
AT1 Quarterly Activity Report & Appendix 4C - 30 September 2020
29/10/20	PRICE SENSITIVE	768.95KB	Share
AT1 Atomo receives TGA approval for COVID19 antigen test
27/10/20	PRICE SENSITIVE	527.41KB	Share
AT1 Trading Halt
27/10/20	PRICE SENSITIVE	308.14KB	Share
AT1 Atomo & Access Bio sign deal for rapid antigen test
29/09/20	PRICE SENSITIVE	516.59KB	Share
AT1 Pause in Trading
29/09/20	PRICE SENSITIVE	116.08KB	Share
AT1 DIVOC Labs to sell Atomo's COVID-19 test in India
23/09/20	PRICE SENSITIVE	331.29KB	Share
AT1 Pause in Trading
23/09/20	PRICE SENSITIVE	116.17KB	Share
AT1 FY20 Results Presentation
31/08/20	PRICE SENSITIVE	2.2MB	Share
AT1 Appendix 4E & Annual Financial Report
31/08/20	PRICE SENSITIVE	4.8MB	Share
AT1 Atomo receives TGA approval for COVID19 antibody test
10/08/20	PRICE SENSITIVE	236.93KB	Share
AT1 Pause in Trading
10/08/20	PRICE SENSITIVE	115.95KB	Share
AT1 Atomo & Access Bio enter North American COVID-19 partnership
28/07/20	PRICE SENSITIVE	416.4KB	Share
AT1 Quarterly Activity Report & Appendix 4C - 30 June 2020
22/07/20	PRICE SENSITIVE	505.42KB	Share
AT1 S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
AT1 Atomo and NG Biotech expand COVID-19 partnership
04/06/20	PRICE SENSITIVE	382.44KB	Share
AT1 Pause in Trading
04/06/20	PRICE SENSITIVE	115.52KB	Share
AT1 Atomo receives additional order for COVID19 test devices
07/05/20	PRICE SENSITIVE	304.18KB	Share
AT1 Pause in Trading
07/05/20	PRICE SENSITIVE	115.75KB	Share

REFRESH

(20min delay)
Last 2.3¢		Change 0.001(4.55%)		Mkt cap ! $14.70M

Open	High	Low	Value	Volume
2.0¢	2.3¢	2.0¢	$1.21K	55.02K

Buyers (Bids)

No.	Vol.	Price($)
5	314348	2.0¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	152314	2

View Market Depth

No.	Vol.	Price($)
5	314348	0.020
5	604260	0.019
9	1162558	0.018
3	410000	0.017
1	62561	0.016

Price($)	Vol.	No.
0.023	99683	1
0.024	631111	3
0.025	459000	2
0.026	1590045	4
0.027	683000	3

Last trade - 16.10pm 04/10/2024 (20 minute delay)


Last 2.1¢		Change 0.001 ( 0.00 %)
Open	High	Low	Volume
2.0¢	2.2¢	2.0¢	78363
Last updated 15.58pm 04/10/2024 ?

AT1 (ASX) Chart

ATOMO DIAGNOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available